A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial

• Published in: Journal of gynecologic oncology 2019, 30(4), , pp.1-13
• Main Authors: Tangjitgamol, Siriwan, Tharavichitkul, Ekkasit, Tovanabutra, Chokaew, Rongsriyam, Kanisa, Asakij, Tussawan, Paengchit, Kannika, Sukhaboon, Jirasak, Penpattanagul, Somkit, Kridakara, Apiradee, Hanprasertpong, Jitti, Chomprasert, Kittisak, Wanglikitkoon, Sirentra, Atjimakul, Thiti, Pariyawateekul, Piyawan, Katanyoo, Kanyarat, Tanprasert, Prapai, Janweerachai, Wanwipa, Sangthawan, Duangjai, Khunnarong, Jakkapan, Chottetanaprasith, Taywin, Supawattanabodee, Busaba, Lertsanguansinchai, Prasert, Srisomboon, Jatupol, Isaranuwatchai, Wanrudee, Lorvidhaya, Vichan
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - mortality; Adenocarcinoma - pathology; Adenocarcinoma - therapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Carboplatin - administration & dosage; Carboplatin - adverse effects; Carcinoma, Squamous Cell - mortality; Carcinoma, Squamous Cell - pathology; Carcinoma, Squamous Cell - therapy; Chemoradiotherapy - adverse effects; Chemotherapy, Adjuvant - adverse effects; Female; Humans; Middle Aged; Original; Paclitaxel - administration & dosage; Paclitaxel - adverse effects; Treatment Outcome; Uterine Cervical Neoplasms - mortality; Uterine Cervical Neoplasms - pathology; Uterine Cervical Neoplasms - therapy; 산부인과학
• ISSN: 2005-0380; 2005-0399
• DOI: 10.3802/jgo.2019.30.e82

To compare response rate and survivals of locally advanced stage cervical cancer patients who had standard concurrent chemoradiation therapy (CCRT) alone to those who had adjuvant chemotherapy (ACT) after CCRT. Patients aged 18-70 years who had International Federation of Gynecology and Obstetrics stage IIB-IVA without para-aortic lymph node enlargement, Eastern Cooperative Oncology Group scores 0-2, and non-aggressive histopathology were randomized to have CCRT with weekly cisplatin followed by observation (arm A) or by ACT with paclitaxel plus carboplatin every 4 weeks for 3 cycles (arm B). Data analysis of 259 patients showed no significant difference in complete responses at 4 months after treatment between arm A (n=129) and arm B (n=130): 94.1% vs. 87.0% (p=0.154) respectively. With the median follow-up of 27.4 months, 15.5% of patients in arm A and 10.8% in arm B experienced recurrences (p=0.123). There were no significant differences of overall or loco-regional failure. However, systemic recurrences were significantly lower in arm B than arm A: 5.4% vs. 10.1% (p=0.029). The 3-year progression-free survival (PFS) and 3-year overall survival (OS) of the patients in both arms were not significantly different. The hazard ratio of PFS and OS of arm B compared to arm A were 1.26 (95% CI=0.82-1.96; p=0.293) and 1.42 (95% CI=0.81-2.49; p=0.221) respectively. ACT with paclitaxel plus carboplatin after CCRT did not improve response rate and survival compared to CCRT alone. Only significant decrease of systemic recurrences with ACT was observed, but not overall or loco-regional failure. ClinicalTrials.gov Identifier: NCT02036164, Thai Clinical Trials Registry Identifier: TCTR 20140106001.